Weekly versus 3‐weekly cisplatin along with radiotherapy for locoregionally advanced non‐nasopharyngeal head and neck cancers: Is the equipoise in literature addressed yet?

Abstract

AbstractConcurrent chemoradiotherapy with 3‐weekly cisplatin 100 mg/m2 has been the standard of care for locoregionally advanced head and neck cancer (LA‐HNC) with level I evidence. While the outcomes in terms of efficacy have been well established, the toxicity profile, compliance, and real‐world applicability has been an area of ongoing concern for this regimen, leading the oncologists to explore weekly cisplatin chemoradiotherapy regimen to potentially address the issue. A review of literature was conducted in Pubmed, Scopus, and Medline to compare and evaluate the present role of weekly cisplatin chemotherapy along with radiotherapy versus 3‐weekly cisplatin chemotherapy along with radiotherapy in both adjuvant and definitive settings for locoregionally advanced head and neck cancers. Nasopharyngeal subsites were excluded from the literature review and 50 relevant articles were included in the analysis. Recently published evidences of noninferiority of weekly over 3‐weekly cisplatin chemoradiotherapy regimen in definitive as well as adjuvant settings in locoregionally advanced head and neck cancers is highlighted and interpreted. Results supporting and against the above in different publications is elaborated in this article. Trials designed to demonstrate noninferiority of the weekly cisplatin chemoradiotherapy regimen over 3‐weekly regimen, especially in definitive setting may conclude the debate in future. A lacunae in the existing literature is noted in the form of lack of superiority trials on the above topic, which may impact future conclusions.